Testing effectiveness (Phase 2)Not Yet RecruitingNCT07175051
What this trial is testing
Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin
Who this might be right for
Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)Albuminuria
University of Illinois at Chicago 20